SEC Form 4 · accession 0001140361-17-010999
RESMED INC · RMD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter C Farrell
Director
Period of report
Mar 6, 2017
Accepted (ET)
Mar 8, 2017 · 3:51 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000943819
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| ResMed Common Stock | Mar 6, 2017 | M | 16,085 | $33.70 | A | 317,642 | D | |
| ResMed Common Stock | Mar 6, 2017 | M | 3,915 | $27.58 | A | 321,557 | D | |
| ResMed Common StockF2 | Mar 6, 2017 | S | 20,000 | $71.70 | D | 301,557 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Resmed Stock Option PlanF3 | $33.70 | Mar 6, 2017 | M | 16,085 | D | Nov 11, 2011 | Nov 11, 2017 | ResMed Common Stock | 16,085 | 0 | D |
| Resmed Stock Option PlanF3 | $27.58 | Mar 6, 2017 | M | 3,915 | D | Nov 11, 2012 | Nov 16, 2018 | ResMed Common Stock | 3,915 | 242,460 | D |
Explanation of responses
- F1The transaction was conducted under a Rule 10b5-1 plan.
- F2This transaction was executed in multiple trades at prices ranging from 71.48 to 71.97. The price reported above represents the weighted average sales price.
- F3Represents date options first became exercisable. Options vested 1/4 per year.